
RadNet RDNT
$ 70.2
-0.43%
Quarterly report 2025-Q3
added 11-10-2025
RadNet Accounts Payables 2011-2026 | RDNT
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables RadNet
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.4 M | 123 M | 103 M | 86.5 M | 70.1 M | 64.3 M | 68 M | 28.5 M | 1 K | 52.3 M | 46.9 M | 37 M | 39.2 M | 873 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | 1 K | 58.3 M |
Quarterly Accounts Payables RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | 86.5 M | - | - | - | 70.1 M | - | - | - | 64.3 M | - | - | - | 68 M | - | - | - | 28.5 M | - | - | - | 41 M | - | - | - | 1 K | - | - | - | 98 K | - | - | - | 658 K | - | - | - | 839 K | - | - | - | 873 K | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 86.5 M | 1 K | 32.8 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
881 K | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 29.0 | -3.07 % | $ 316 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
6.96 M | $ 1.14 | -2.16 % | $ 1.45 M | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
9.37 M | $ 104.95 | -1.72 % | $ 4.14 B | ||
|
Co-Diagnostics
CODX
|
1.48 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
1.75 B | $ 210.56 | -0.33 % | $ 154 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 29.41 | -6.17 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Quest Diagnostics Incorporated
DGX
|
287 M | $ 202.21 | -0.11 % | $ 22.4 B | ||
|
DexCom
DXCM
|
344 M | $ 73.08 | 1.11 % | $ 28.5 B | ||
|
DarioHealth Corp.
DRIO
|
1.13 M | $ 11.75 | 2.8 % | $ 333 M | ||
|
CareDx, Inc
CDNA
|
12.9 M | $ 18.83 | -5.23 % | $ 1.01 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Illumina
ILMN
|
221 M | $ 117.53 | -2.06 % | $ 18.7 B | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 23.18 | -0.39 % | $ 701 M | ||
|
Exact Sciences Corporation
EXAS
|
176 M | $ 103.45 | 0.15 % | $ 19.5 B | ||
|
Lantheus Holdings
LNTH
|
34.6 M | $ 74.31 | 1.54 % | $ 5.14 B | ||
|
Guardant Health
GH
|
54.4 M | $ 103.36 | -2.84 % | $ 13 B | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 99.61 | 1.22 % | $ 8.22 B | ||
|
Interpace Biosciences
IDXG
|
1.66 M | $ 1.85 | 2.78 % | $ 8.12 M | ||
|
QIAGEN N.V.
QGEN
|
83.3 M | - | - | $ 10.6 B | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 169.68 | 3.11 % | $ 8.41 B | ||
|
IDEXX Laboratories
IDXX
|
114 M | $ 635.6 | 0.77 % | $ 52.4 B | ||
|
IQVIA Holdings
IQV
|
322 M | $ 166.19 | -1.87 % | $ 28.6 B | ||
|
Biodesix
BDSX
|
2.19 M | $ 13.26 | 4.0 % | $ 1.72 B | ||
|
Laboratory Corporation of America Holdings
LH
|
876 M | $ 283.38 | 0.32 % | $ 23.8 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.17 | -2.25 % | $ 4.98 M | ||
|
Bioventus
BVS
|
23 M | $ 8.57 | -0.06 % | $ 537 M | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 452.99 | 1.47 % | $ 13.1 B | ||
|
National Research Corporation
NRC
|
1.3 M | $ 13.65 | 9.64 % | $ 335 M | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 378.44 | 0.14 % | $ 28.4 B |